Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1200/JOP.2017.024836 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Efficacy and Safety of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin and Prednisone for Previously Untreated Diffuse Large B-Cell Lymphoma: A Real-World, Multi-Center, Retrospective Cohort Study.
Hematol Oncol
January 2025
Department of Lymphoma, Tianjin's Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin Medical University Cancer Institute and Hospital, Tianjin Medical University, Tianjin, China.
Polatuzumab vedotin plus R-CHP (Pola-R-CHP) is approved as a new standard first-line therapy for diffuse large B-cell lymphoma (DLBCL) based on the POLARIX trial. However, real-world data on its efficacy and safety in unselected patients is lacking. We conducted a retrospective cohort study to evaluate Pola-R-CHP versus R-CHOP outcomes in routine clinical practice in China.
View Article and Find Full Text PDFNon-Hodgkin's primary lymphoma involving the genitourinary tract: histopathological experience from two tertiary hospitals, Western region, Saudi Arabia.
Am J Clin Exp Urol
October 2024
Department of Pathology and Laboratory Medicine, King Faisal Specialist Hospital and Research Center Jeddah, Saudi Arabia.
Article Synopsis
- The study focuses on primary lymphoid neoplasms in the urinary tract and male genital organs, which are rare and make up less than 5% of extranodal lymphomas.
- Researchers analyzed cases diagnosed from 2005 to 2020, examining pathology slides from 11 patients, predominantly middle-aged, finding a female predominance in urinary bladder and ureter lymphomas.
- The findings confirm that diffuse large B-cell lymphoma (DLBCL) is the most common subtype, but emphasize the importance of thorough classification and diagnosis using techniques like immunohistochemistry to accurately identify various lymphoma types.
Tumor Biology Hides Novel Therapeutic Approaches to Diffuse Large B-Cell Lymphoma: A Narrative Review.
Int J Mol Sci
October 2024
Department of Physical Chemistry, Vinca Institute of Nuclear Sciences-National Institute of the Republic of Serbia, University of Belgrade, Mike Petrovica Alasa 12-14, 11000 Belgrade, Serbia.
Diffuse large B-cell lymphoma (DLBCL) is a malignancy of immense biological and clinical heterogeneity. Based on the transcriptomic or genomic approach, several different classification schemes have evolved over the years to subdivide DLBCL into clinically (prognostically) relevant subsets, but each leaves unclassified samples. Herein, we outline the DLBCL tumor biology behind the actual and potential drug targets and address the challenges and drawbacks coupled with their (potential) use.
View Article and Find Full Text PDFNovel diagnostic method for B cell vitreoretinal lymphoma by identification of regulatory T cells and PD-1 cytotoxic T lymphocytes in the vitreous via flow cytometry.
Br J Ophthalmol
October 2024
Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan.
Aims: To investigate the significance of regulatory T cells (Tregs) and programmed cell death 1 (PD-1) cytotoxic T lymphocytes (CTLs) in the vitreous of patients with vitreoretinal lymphoma (VRL) and uveitis.
Methods: This study involved 51 patients with VRL and uveitis, 15 males and 36 females (mean age: 72 years, range: 51-86 years), who underwent vitrectomy at the Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan, from December 2019 to February 2024. All patients underwent lymphocyte surface antigen analysis via flow cytometry, and the proportion of Tregs in CD4 T lymphocytes and PD-1 CTLs in CD8 T lymphocytes was measured.
Advances in biology, diagnosis and treatment of DLBCL.
Ann Hematol
September 2024
Department of Hematology, The First Affiliated Hospital, Zhejiang University School of Medicine, No. 79 Qingchun Road, Hangzhou, 310003, Zhejiang, China.
Diffuse large B-cell lymphoma (DLBCL), with approximately 150,000 new cases worldwide each year, represent nearly 30% of all cases of non-Hodgkin lymphoma (NHL) and are phenotypically and genetically heterogeneous. A gene-expression profile (GEP) has identified at least three major subtypes of DLBCL, each of which has distinct clinical, biological, and genetic features: activated B-cell (ABC)-like DLBCL, germinal-center B-cell (GCB)-like DLBCL, and unclassified. Different origins are associated with different responses to chemotherapy and targeted agents.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!